Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms 7Sarcoma 3Multiple Myeloma 3Leukemia 3Kidney Neoplasms 3Glioma 3Brain Neoplasms 3Waldenstrom Macroglobulinemia 2Sarcoma, Alveolar Soft Part 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Oligodendroglioma 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioblastoma 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Astrocytoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Myeloproliferative Disorders 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Recurrence × perifosine × Clear all
NCT00401011 2018-02-23

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

AEterna Zentaris

Phase 1/2 Completed
84 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01049841 2017-03-10

Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
23 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡